Janssen Collaborates with BARDA to Facilitate the Development of Corona Virus Vaccine
Janssen, Imbruvica, (ibrutinib), Receives, EC, Marketing Authorisation, Approval, Chronic Lymphocytic Leukaemia
Shots:
- Janssen partnered with BARDA to accelerate the development of its investigational coronavirus vaccine program. Both will partake to the research and development cost and mobilize resources to advance Janssen’s COVID-19 vaccine program
- BARDA to provide a fund to expedite the development of vaccine into P-I study with an option for additional funding to advance a promising candidate while Janssen will upscale the production capacities to meet the public health needs
- COVID-19 vaccine program will leverage Janssen’s AdVac and PER.C6 technologies, providing the ability to upscale production of the optimal vaccine therapy. The company utilizes its same technology in its Ebola vaccine, currently being administered in the Democratic Republic of Congo and Rwanda
Click here to read full press release/ article | Ref: J & J | Image: Janssen